跳到正文
cccskills
免费在 GitHub 公开

enda-monitor-glucocorticoid-replacement

Monitors glucocorticoid replacement in primary adrenal insufficiency (PAI) patients using clinical assessment of body weight, postural blood pressure, energy levels, and signs of frank glucocorticoid excess. Trigger phrases include "PAI patient on glucocorticoid replacement," "assess for weight gain or insomnia," and "evaluate for postural hypotension or fatigue."

中文简介正在准备中。当前显示原文说明。

实测评分 未实测

查看安装方法

包含的文件(1)

  • SKILL.md2.4 KB

SKILL.md(原文)

安装前可以查看交给 AI 代理的指令内容。

Monitor Glucocorticoid Replacement via Clinical Assessment

STEP 1 — Gather Information

Measure body weight, sitting and standing blood pressure (postural change), query energy levels (fatigue, lethargy, insomnia), and inspect for signs of glucocorticoid excess (weight gain, central obesity, peripheral edema, hyperglycemia, skin thinning) or insufficiency (hyperpigmentation, salt craving, weight loss, postural hypotension).

STEP 2 — Rule In / Rule Out

Determine if any signs of glucocorticoid excess are present; if yes, proceed to assess for over-replacement, if no, proceed to assess for under-replacement.

STEP 3 — Classify or Stratify

Classify the patient as glucocorticoid excess (≥2 excess signs), adequate (no excess or insufficiency signs), or insufficiency (≥2 insufficiency signs such as fatigue, weight loss, postural hypotension, hyperpigmentation).

STEP 4 — Decide

If excess: consider glucocorticoid dose reduction by 10‑20%; if insufficiency: consider dose increase by 10‑20%; if adequate: maintain current dose and schedule routine reassessment in 3‑6 months.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on serum cortisol or ACTH for dose adjustments; avoid using dexamethasone for replacement due to Cushingoid risk; do not make dose changes based on a single vital sign; consider concomitant medications that alter cortisol metabolism (e.g., phenytoin, rifampicin); remember that weight alone can be misleading in edema or sarcopenia.

Concrete Clinical Example

A 50‑year‑old man with PAI on hydrocortisone 25 mg daily reports 3 kg weight gain, insomnia, and mild ankle edema over 2 months; BP 128/78 mm Hg sitting, 122/76 mm Hg standing; energy low. Assessment shows excess signs (weight gain, insomnia, edema). Decision: reduce hydrocortisone to 20 mg daily, re‑evaluate in 4 weeks.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2015-1710

评价

还没有评价。欢迎分享你的使用感受。

评论

无需登录即可发表。欢迎分享使用感受、提问,或说明在哪些环境下无法运行。

还没有评论。来写第一条吧。

提交后会立即公开。请勿填写邮箱、电话等个人信息。URL 最多 2 个。

0 / 1000 字

此表单受 reCAPTCHA 保护,适用 Google 的隐私权政策和服务条款。

同一仓库的技能

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

查看 dromlakhani 的全部技能

报告此技能的问题